How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
about
Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in IcelandGenetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.
P2860
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
description
scientific article published on 30 June 2015
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2015
@uk
name
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
@en
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
@nl
type
label
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
@en
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
@nl
prefLabel
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
@en
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
@nl
P2860
P356
P1433
P1476
How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?
@en
P2860
P304
P356
10.2217/PGS.15.67
P577
2015-06-30T00:00:00Z